Home › Compare › SOFE vs ABBV

SOFE vs ABBV: Dividend Comparison 2026

SOFE yields 125000.00% · ABBV yields 3.12%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SOFE wins by $4.4870750575756587e+27M in total portfolio value
10 years
SOFE
SOFE
● Live price
125000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.4870750575756587e+27M
Annual income
$4,480,024,748,164,424,300,000,000,000,000,000.00
Full SOFE calculator →
ABBV
AbbVie Inc.
● Live price
3.12%
Share price
$213.22
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$104.7K
Annual income
$25,725.73
Full ABBV calculator →

Portfolio growth — SOFE vs ABBV

📍 SOFE pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSOFEABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SOFE + ABBV cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
SOFE pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SOFE
Annual income on $10K today (after 15% tax)
$10,625,000.00/yr
After 10yr DRIP, annual income (after tax)
$3,808,021,035,939,760,400,000,000,000,000,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$265.10/yr
After 10yr DRIP, annual income (after tax)
$21,866.87/yr
At 15% tax rate, SOFE beats the other by $3,808,021,035,939,760,400,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SOFE + ABBV for your $10,000?

SOFE: 50%ABBV: 50%
100% ABBV50/50100% SOFE
Portfolio after 10yr
$2.2435375287878293e+27M
Annual income
$2,240,012,374,082,212,200,000,000,000,000,000.00/yr
Blended yield
99.84%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

SOFE
No analyst data
Altman Z
-0.4
Piotroski
3/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+20.1% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SOFE buys
0
ABBV buys
0
No recent congressional trades found for SOFE or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSOFEABBV
Forward yield125000.00% ✓3.12%
Annual dividend / share$2.00$6.65 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6% ✓
Portfolio after 10y$4.4870750575756587e+27M$104.7K ✓
Annual income after 10y$4,480,024,748,164,424,300,000,000,000,000,000.00 ✓$25,725.73
Total dividends collected$4.486613188508161e+27M$63.0K ✓
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SOFE vs ABBV ($10,000, DRIP)

YearSOFE PortfolioSOFE Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$12,510,700$12,500,000.00$11,559$438.51+$12.50M → SOFE
2$14,628,690,187$14,615,303,738.32$13,494$640.86+$14628.68M → SOFE
3$15,987,233,390,392$15,971,580,691,892.04$15,951$945.97+$15987233.37M → SOFE
4$16,330,037,182,147,600$16,312,930,842,419,880.00$19,152$1,413.89+$16330037182.13M → SOFE
5$15,590,107,113,307,974,000$15,572,633,973,523,075,000.00$23,443$2,146.38+$15590107113307.95M → SOFE
6$13,911,095,050,184,500,000,000$13,894,413,635,573,263,000,000.00$29,391$3,321.96+$13911095050184500.00M → SOFE
7$11,601,822,386,032,217,000,000,000$11,586,937,514,328,520,000,000,000.00$37,948$5,265.87+$11601822386032216064.00M → SOFE
8$9,043,703,820,318,592,000,000,000,000$9,031,289,870,365,538,000,000,000,000.00$50,795$8,596.74+$9.043703820318592e+21M → SOFE
9$6,589,074,216,106,539,000,000,000,000,000$6,579,397,453,018,798,000,000,000,000,000.00$71,034$14,549.41+$6.589074216106539e+24M → SOFE
10$4,487,075,057,575,658,400,000,000,000,000,000$4,480,024,748,164,424,300,000,000,000,000,000.00$104,715$25,725.73+$4.4870750575756587e+27M → SOFE

SOFE vs ABBV: Complete Analysis 2026

SOFE — Stock

Carepay Inc. operates as a healthcare IT company. Its SOAFEE platform allow consumers to find affordable self-pay pricing for all of their medical needs. The company is based in Bellaire, Texas.

Full SOFE Calculator →

ABBV — Healthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this SOFE vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SOFE vs SCHDSOFE vs JEPISOFE vs OSOFE vs KOSOFE vs MAINSOFE vs JNJSOFE vs MRKSOFE vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.